Negative Pressure Wound Therapy (NPWT) : Principles and Applications A-Young Lee (李雅永) Ph.D. Academic support, Daewoong Pharmaceutical
Ancient Cupping Therapy Ge Hong (281-341 A.D) “Acupuncture and cupping, more than half of the ills cured”
Evolution of NPWT Foam KulaVAC® -Daewoong 1995: Wound VAC®– KCI 1947, Russia Post-op exudate management Wall Suction & Gauze Foam KulaVAC® -Daewoong EZ Care™ - Smith & Nephew Engenex® (Boehringer Wound Systems) – ConvaTec Genadyne A4 – Genadyne Biotechnologies Inc. Kalypto - Kalypto Medical Medela® - Invia MoblVac® - Ohio Medical Prodigy™ - Premco Medical Systems, Inc. Prospera PRO-I™ & PRO-II™ Systems – Medica Renasys – Smith & Nephew Svedman™ & Sved™ Systems - Innovative Therapies Venturi™ System - Talley Group 1952 Closed suction used prophylactically to reduce Post-op complications
NPWT on Wound Healing Promotes Granulation tissue formation Provide moist wound environment Removes Exudate Infectious materials Mechanical/ Biological Forces Angiogenesis & ↑perfusion Cell migration & proliferation Promotes Granulation tissue formation
Composition of KulaVAC® Components Foam Dressing (Three Different Sizes) Film Dressing Accessories (Suction Head, Tubing with Connectors and Clamp)
Features of KulaVAC® Polyurethane Foam hydrophobic, prevents Contamination from exudate. Prevents ingrowth of granulation tissue Pore size : 400-600 μm
KulaVAC® Bridge
KulaVAC® Silver
2. The world’s first cyclic Mode of Curasys® Features of Curasys® 1. Portability Weight 890g Up to 12 hours of battery life A/C or battery operational 2. The world’s first cyclic Mode of Curasys® Increased vascular Perfusion Faster wound closure Reduced pain
KulaVAC® on Various Indications Dehisced Wound DM Foot Pressure Ulcer Trauma
KulaVAC® on Various Indications Skin Graft Open Abdomen Burn
KulaVAC® Publications
KulaVAC® Publications
KulaVAC® Publications Intermittent mode Cyclic mode
KulaVAC® Clinical Trial on Trauma Effects of Incisional NPWT on High-energy Foot & Ankle Trauma - A Prospective, Multicenter, Randomized Controlled Trial- High risk of Wound dehiscence, Marginal necrosis, Infection Infection/Dehiscence rate Pilon Fx: 5~40% Calcaneal Fx: 0~25% (본 연구는 CG Bio의 후원으로 이루어졌음.)